# An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation

> **NCT06466486** · PHASE1 · TERMINATED · sponsor: **Ferring Pharmaceuticals** · enrollment: 310 (actual)

## Conditions studied

- Fertility

## Interventions

- **DRUG:** Follitropin delta
- **DRUG:** FE999302
- **DRUG:** FE999302 Placebo

## Key facts

- **NCT ID:** NCT06466486
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-06-14
- **Primary completion:** 2025-12-03
- **Final completion:** 2025-12-03
- **Target enrollment:** 310 (ACTUAL)
- **Why stopped:** This is a company decision made not related to safety concerns. Rather, it reflects a broader portfolio assessment and the desire to focus on programs that can bring timely and meaningful benefit to patients.
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06466486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06466486, "An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06466486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*